Although clinical trials of agents that block IL-23 or IL-1β have not been conducted in patients with asthma, future studies are required to elucidate the potential of treatments targeting IL-23 or IL-1β as novel therapeutic strategies for steroid-insensitive asthma. This evidence concerns the gene IL1B and asthma.